What are the ATA guidelines on radioiodine therapy in the treatment of thyroid cancer?

Updated: Jun 24, 2020
  • Print
Answer

Answer

The ATA recommends radioiodine therapy for all patients if any of the following are present: [1]

  • Distant metastases
  • Extrathyroidal extension of the tumor regardless of tumor size
  • Primary tumor size >4 cm even in the absence of other higher-risk features.

Radioiodine therapy is not recommended for patients with unifocal cancer < 1 cm without other higher- risk features; or for patients with multifocal cancer when all foci are < 1 cm in the absence of other higher-risk features. [1]

Radioiodine therapy is also recommended for selected patients with 1-4–cm thyroid cancers confined to the thyroid who have documented lymph node metastases or other higher risk features, when the combination of age, tumor size, lymph node status, and individual histology predicts an intermediate to high risk of recurrence or death from thyroid cancer. [1]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!